Crucell

Crucell up on MedImmune deal

Crucell up on MedImmune deal

By Anna Lewcock

Following the shaky moment Crucell experienced last month after the
failure of Merck's HIV drug, share prices had a healthy boost this
morning on the news that MedImmune will be collaborating with the
Dutch firm to develop new...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers